
## CLAIMS

1. Use of an IL-8 inhibitor in the manufacture of a medicament for the prevention and/or treatment of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma or rhabdomyosarcoma, more preferably in the prevention and/or treatment of lung metastasis associated to osteosarcoma, Ewing sarcoma or rhabdomyosarcoma.
2. The use according to claim 1, wherein the IL-8 inhibitor is selected from small molecular weight molecules and antibodies, preferably said IL-8 inhibitor is an inhibitor of the activity of IL-8 mediated by the CXCR1 receptor or by both the CXCR1 and CXCR2 receptor.
3. The use according to claim 1 or claim 2, wherein the IL-8 inhibitor is selected from 1,3-thiazol-2-ylaminophenylpropionic acid derivatives, 2-phenyl-propionic acid derivatives and their pharmaceutically acceptable salts.
4. The use according to claim 3, wherein said 1,3-thiazol-2-ylaminophenylpropionic acid derivatives are compounds of formula (I)




**(I)**

wherein

-R1 is hydrogen or $CH_3$;

-R2 is hydrogen or linear $C_1$-$C_4$ alkyl, preferably it is hydrogen;

-Y is a heteroatom selected from S, O and N; preferably it is S;

-Z is selected from halogen, linear or branched $C_1$-$C_4$ alkyl, $C_2$-$C_4$ alkenyl, $C_2$-$C_4$ alkynyl, $C_1$-$C_4$ alkoxy, hydroxyl, carboxyl, $C_1$-$C_4$ acyloxy, phenoxy, cyano, nitro, amino, $C_1$-$C_4$ acylamino, halo $C_1$-$C_3$ alkyl, halo $C_1$-$C_3$ alkoxy, benzoyl, linear or branched $C_1$-$C_8$ alkanesulfonate, linear or branched $C_1$-$C_8$ alkanesulfonamide, linear or branched $C_1$-$C_8$ alkylsulfonylmethyl; preferably it is trifluoromethyl;

-X is OH or a residue of formula $NHR_3$; wherein $R_3$ is selected from:

-hydrogen, hydroxyl, linear or branched $C_1$-$C_6$ alkyl, $C_3$-$C_6$ cycloalkyl, $C_2$-$C_6$ alkenyl, $C_1$-$C_5$ alkoxy,

or $C_1$-$C_6$ phenylalkyl, wherein alkyl, cycloalkyl or alkenyl group can be substituted by a COOH residue

- a residue of formula $SO_2R4$ wherein R4 is $C_1$-$C_2$ alkyl, $C_3$-$C_6$ cycloalkyl, $C_1$-$C_3$ haloalkyl.

5. The use according to claim 4, wherein: R1 is hydrogen or $CH_3$;

X is OH;

R2 is hydrogen or linear $C_1$-$C_4$ alkyl,

Y is a heteroatom selected from S, O and N;


Z is selected from linear or branched $C_1$-$C_4$ alkyl, linear or branched $C_1$-$C_4$ alkoxy, halo $C_1$-$C_3$ alkyl and halo $C_1$-$C_3$ alkoxy.

6. The use according to claim 4, wherein R1 is hydrogen, the chiral carbon atom of the phenylproprionic group is in the S configuration.

7. The use according to any of claims 3, 4 or 5, wherein the IL-8 inhibitor is selected from 2-methyl-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino} phenyl) propanoic acid and pharmaceutically acceptable salts thereof, preferably its sodium salt.

8. The use according to any of claims 3 to 6, wherein said compound is (2S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl] amino} phenyl) propanoic acid and pharmaceutically acceptable salts thereof, preferably its sodium salt.

9. The use according to claim 3, wherein said 2-phenyl-propionic acid derivatives are compounds of formula (II)



(II)

or a pharmaceutically acceptable salt thereof,


wherein:

$R^4$ is linear or branched $C_1$-$C_6$ alkyl, benzoyl, phenoxy, trifluoromethanesulfonyloxy; preferably it is selected from benzoyl, isobutyl and trifluoromethanesulfonyloxy. Also, according to a preferred embodiment $R^4$ is in position 3 or 4 on the phenyl ring, more preferably it is 3-benzoyl, 4-isobutyl or 4-trifluoromethanesulfonyloxy:

$R^5$ is H or linear or branched $C_1$-$C_3$ alkyl, preferably it is H;

$R^6$ is linear or branched $C_1$-$C_6$ alkyl or trifluoromethyl; preferably, it is a linear or branched $C_1$-$C_6$ alkyl, more preferably it is $CH_3$.

10. The use according to claim 3, wherein said 2-phenyl-propionic acid derivatives are compounds of formula (III)



(III)

or a pharmaceutically acceptable salts thereof,

wherein

R' is hydrogen;

R is a residue of formula $SO_2Ra$ wherein Ra is linear or branched $C_1$-$C_4$ alkyl or halo $C_1$-$C_3$ alkyl, preferably it is $CH_3$.

11. The use according to claim 9 or claim 10, wherein the chiral carbon atom of the phenylpropionic group is in the R configuration.

12. The use according to claim 9, wherein said compound is selected from R-(-)-2-(4-isobutylphenyl)propionyl methanesulfonamide and pharmaceutically acceptable salts thereof, preferably the lysine *in situ* salt.

13. The use according to any of claims 9 to 11, wherein said compound is R(-)-2-(4-trifluoromethanesulfonyloxy)phenyl]-N-methanesulfonyl propionamide and pharmaceutically acceptable salts thereof, preferably its sodium salt.

14. The use according to any of the previous claims wherein the medicament is in the form of a pharmaceutical composition including pharmaceutically acceptable excipients and/or diluents.

15. The use according to claim 14, further comprising at least one IL-6 inhibitor and/or at least one gp130 inhibitor.

16. The use according to claim 14, further comprising at least one chemotherapeutic agent, preferably selected from the group comprising doxorubicin, cisplatin, methotrexate, ifosfamide, epirubicin, etoposide, cyclophosphamide, vincristine and actinomycin D.

17. A product or a kit comprising:

A) an IL-8 inhibitor according to any one of claims 1 to 13, or a pharmaceutical composition according to claim 14, and

B) at least one IL-6 inhibitor and/or at least one gp130 inhibitor,

A) and B) being two separate formulations for simultaneous, separate or sequential use.

18. A product or a kit comprising:

A') an IL-8 inhibitor according to any one of claims 1 to 13, or a pharmaceutical composition according to claim 14, and

B') at least one chemotherapeutic agent, preferably selected from the group comprising doxorubicin, cisplatin, methotrexate, ifosfamide, epirubicin, etoposide, cyclophosphamide, vincristine and actinomycin D,

A') and B') being two separate formulations for simultaneous, separate or sequential use.